Targeting Metabolic Reprogramming to Radiosensitize Glioblastoma Stem Cells

Targeting Metabolic Reprogramming to Radiosensitize Glioblastoma Stem Cells

Cleveland Clinic

4 months
25 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Kailin Yang, MD of Cleveland Clinic discusses targeting metabolic reprogramming to radiosensitize glioblastoma stem cells.

_________

Inhibiting two critical steps in the metabolism of glioblastoma stem cells (GSCs) attenuates GSC self-renewal and reduces tumorigenesis, finds a new study presented at the 2019 annual meeting of the American Society for Radiation Oncology (ASTRO).

“Determining how to target glioma stem cells effectively has been a major challenge in treating glioblastoma [GBM],” says Kailin Yang, MD, PhD, a radiation oncology resident at Cleveland Clinic Cancer Center who presented the abstract under the supervision of Jeremy Rich, MD, MHS, of the University of California at San Diego. “Our previous studies suggested that pyrimidine synthesis is associated with clinical outcome in glioblastoma patients, and thus is a productive place to focus our energy.”

The current study demonstrates that simultaneous targeting of two vital enzymes in the pyrimidine synthetic pathway inhibits self-renewal and tumorigenesis of GSCs.

The first enzyme is rate-limiting carbamoyl-phosphate synthetase 2, aspartate transcarbamyolase, dihydroorotase (CAD). EGFR or PTEN driver mutations demonstrated distinct CAD phosphorylation patterns. The second, dihydroorotate dehydrogenase (DHODH), catalyzes the subsequent step in pyrimidine synthesis after CAD. Targeting both enzymes with clinically approved inhibitors produced sustained inhibition of the survival, self-renewal and in vivo tumor initiation of GSCs in patient-derived xenografts, when compared with single treatments.

Read the rest here: https://consultqd.clevelandclinic.org/metabolic-reprogramming-a-promising-approach-to-tackling-therapeutic-resistance-in-glioblastoma/ 

Up Next Autoplay
Pacific Brain Tumor Center Recruiting Patients with Rare Cancer of the Skull and Spine for Groundbreaking Clinical Trial
Pacific Brain Tumor Center Recruiting Patients with Rare Cancer of the Skull and Spine for Groundbreaking Clinical Trial
Category: Brain Cancer
5 Views
Cancer-News 1 week
Mount Sinai Receives More Than $10 Million in Grant Funding for Brain Tumor Research
Mount Sinai Receives More Than $10 Million in Grant Funding for Brain Tumor Research
Category: Brain Cancer
6 Views
Cancer-News 2 weeks
Clinical Efficacy of Weekly ONC201 in Adult Recurrent Glioblastoma Published
Clinical Efficacy of Weekly ONC201 in Adult Recurrent Glioblastoma Published
Category: Brain Cancer
15 Views
alexvarney 2 months
Predicting Tumor Recurrence: How Does This Help Us?
Predicting Tumor Recurrence: How Does This Help Us?
Category: Brain Cancer
9 Views
Baylor College of Medicine 3 months
Predicting Tumor Recurrence
Predicting Tumor Recurrence
Category: Brain Cancer
20 Views
Baylor College of Medicine 3 months
How does this affect clinicians today?
How does this affect clinicians today?
Category: Brain Cancer
10 Views
Cleveland Clinic 4 months
Oncoceutics Commemorates National Childhood Cancer Awareness Month
Oncoceutics Commemorates National Childhood Cancer Awareness Month
Category: Brain Cancer
19 Views
alexvarney 4 months
Publication Reports Clinical Efficacy of ONC201 in Expanded Access H3 K27M-mutant Glioma Patients
Publication Reports Clinical Efficacy of ONC201 in Expanded Access H3 K27M-mutant Glioma Patients
Category: Brain Cancer
39 Views
alexvarney 4 months
Oncoceutics Announces FDA Acceptance of Investigational New Drug Application for Phase I Trial of ONC206
Oncoceutics Announces FDA Acceptance of Investigational New Drug Application for Phase I Trial of ONC206
Category: Brain Cancer
42 Views
alexvarney 4 months